5 Results for "

high in vitro metabolic stability

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "high in vitro metabolic stability" in MCE Product Catalog:

Cat. No.: HY-155813
CAS No.: 3032440-80-2
Target:  

SARS-CoV

Research Areas:  

Infection

MPI60 is a potent SARS-CoV-2 M Pro inhibitor with high antiviral potency, low cellular cytotoxicity, and high in vitro metabolic stability. MPI60 can be used for SARS-CoV-2 research .
loading...
    loading...
Cat. No.: HY-16750
CAS No.: 1314795-11-3
Synonyms: GS-9669
Target:  

DNA/RNA Synthesis HCV

Research Areas:  

Infection

Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC50 = 2.9 nM, GT1b EC50 = 6 nM) .
loading...
    loading...
Cat. No.: HY-122229
CAS No.: 2219362-41-9
Target:  

HIV

Research Areas:  

Infection

GS-9822 is a potent antivira agent with nanomolar activity against wild-type HIV-1 viruses. GS-9822 potently inhibits the LEDGF/p75-integrase interaction with an IC50 of 0.07 μM. GS-9822 has high in vitro metabolic stability and favorable oral pharmacokinetic profiles with low systemic clearance in rats, dogs, and monkeys .
loading...
    loading...
Cat. No.: HY-W237439
CAS No.: 958712-85-1
Target:  

MDM-2/p53

Research Areas:  

Cancer

SEN205A is a fragment compound that binds to the hydrophobic pocket of human S100B (Kd=0.5-1.0 mM), which is the key region for the interaction of S100B with TRTK-12 and p53, and SEN205A can be displaced from this site by TRTK-12. SEN205A exhibits excellent in vitro ADME properties, including high metabolic stability, chemical stability, and good solubility under physiological pH conditions. SEN205A can serve as a starting fragment for structure-based optimization to develop inhibitors targeting the S100B-p53 protein-protein interaction and investigate the pathogenesis of malignant melanoma .
loading...
    loading...
Cat. No.: HY-W663179
CAS No.: 681492-17-1
Research Areas:  

Infection

DNDI-VL-2098 is an orally active antileishmanial agent. DNDI-VL-2098 exhibits high permeability, in vitro metabolic stability, and selective inhibition of CYP2C19 (IC50=0.47 μM). DNDI-VL-2098 does not affect the activities of other major CYP enzymes (CYP1A2, CYP2C9, CYP2D6 and CYP3A4) at concentrations up to 12.5 μM. It shows favorable pharmacokinetic properties in multiple animal models including mice, hamsters, rats and dogs. DNDI-VL-2098 is characterized by moderate to high plasma protein binding and can be used for the research of visceral leishmaniasis .
loading...
    loading...